Pharmacy rebates have long been a major component of PBM contracting and pharmacy benefit economics. As PBM pricing models evolve, understanding how rebates work today, and how they are represented in contracts, has increasingly become important for evaluating overall value.
In today’s market, there is a clear shift toward what is often called a net cost model, where ingredient costs, dispensing fees, and rebate value are viewed together. Under these models, financial guarantees may be structured on a per-claim or per member per month (PMPM) basis. At the same time, so-called rebate-free or rebate reduced approaches aim to move away from the traditional high list price model paired with back-end rebates by converting rebate dollars into upfront discounts, embedded net pricing, or alternative administrative fee structures.
Understanding how rebates work and how they are being repackaged has become essential for evaluating PBM proposals, guarantees, and ongoing performance.
Rebate Fundamentals
Pharmacy rebates originate well before a prescription is filled. Drug manufacturers negotiate rebate arrangements with PBMs in exchange for formulary placement, preferred status, or other utilization-driving strategies. These negotiations are designed to influence utilization, with rebate dollars ultimately reducing a plan’s net cost over time.
Pharmacy rebates are most commonly associated with branded and specialty drugs, where list prices are higher and manufacturer competition for formulary access is more concentrated. While rebates are often discussed at the claim level, their financial impact is typically realized after the point of sale through periodic reconciliation cycles.
How pharmacy rebate value flows to a plan depends heavily on contract structure. Guarantees may be set on a per-claim basis, aggregate basis, or embedded within broader pricing or net cost frameworks. Some contracts emphasize minimum rebate guarantees tied to specific channels or drug categories, while others rely on percentage pass-through provisions. Clear definitions, exclusions, and reconciliation terms ultimately determine how rebate value is calculated, attributed, and validated.
Market Changes
Guarantees: Structure Versus Performance
Net cost describes how pricing is presented, not how outcomes are guaranteed. Guarantees are layered on top of that framework, often through per claim or PMPM arrangements. These may include aggregate rebate minimums by channel or drug category, flat per-claim guarantees, or broader PMPM guarantees based on total net cost across member months.
PMPM guarantees can improve budget predictability by smoothing costs across a covered population. However, pharmacy rebate value is often embedded within these guarantees rather than reported separately and certain drug categories or channels may be partially or fully excluded. As a result, visibility into which drugs, classes, or utilization trends are driving performance may be reduced.
Rebate-Free Models
Alongside net cost models, rebate-free approaches have gained attention. These models are designed to reduce reliance on high list prices paired with large back-end rebates by lowering upfront prices. While the structure differs from the traditional rebate-based arrangements, rebate dollars are not necessarily eliminated. In many cases, they are converted into upfront discounts, embedded within pricing guarantees, or offset through different administrative or service fee arrangements.
A related development is the increased promotion of point-of-sale (POS) rebates, where some rebate value is applied at the pharmacy counter instead of being reconciled retrospectively. POS rebates can lower out-of-pocket costs in coinsurance-based benefit designs but may reduce rebate income available to offset overall plan costs.
Rebate Credits
Rebate credits represent another layer of complexity. As biosimilars gain market share and policy or market pressures compress list prices, traditional rebate streams may decline. Rebate credits allow PBMs to remain compliant with previously negotiated guarantees despite these structural shifts. While these credits be a response to real economic changes, they also make it more difficult to distinguish between rebate performance and accounting or contractual adjustments.
Drug-Level Rebate Models
More recently, drug-level rebate models have emerged that tie specific National Drug Codes (NDCs) to predefined tiers, with each tier carrying its own rebate percentages off wholesale acquisition cost (WAC) rather than a flat dollar guarantee. While they are often framed as more precise, they also introduce greater variability and complexity. Changes in tier assignments, formulary placement, or WAC trends can affect rebate performance. This allows PBMs additional levers to manage pharmacy rebate outcomes as utilization changes.
Key Outlook on Rebates Over the Next Year
Pharmacy rebate structures are expected to keep diversifying, with no single model likely to dominate. Instead, PBMs are experimenting across pricing frameworks, guarantees, and rebate mechanics in response to regulatory pressure, market disruption, and continued change in the drug pipeline.
Regulatory scrutiny is also accelerating, including the FTC’s focus on PBM transparency, vertical integration, and rebate-driven incentives. These developments may increase pressure to favor lower-cost formulary options, apply a greater share of rebate value at the point of sale in certain models, and expand requirements for drug and contract-level reporting.
Several trends are worth monitoring:
- Greater variation in rebate structures rather than uniform adoption of rebate-free pricing
- Continued embedding of rebate value into broader net cost and PMPM guarantees
- Increased formulary movement tied to wholesale acquisition cost dynamics and biosimilar availability
- More detailed reporting without a corresponding reduction in analytical complexity
Expanded transparency requirements may provide more data, but data alone does not validate contract compliance or guarantee performance. As pharmacy rebates become more granular and formula-driven, clear definitions, exclusions, and reconciliation logic matter more than ever. Knowing how value is created, used, and measured will stay key as pharmacy benefit pricing changes.
Truveris is a leading digital health company focused on delivering truth and clarity in pharmacy. Truveris’ proprietary technology, coupled with deep pharmacy expertise, helps to build a more efficient market that maximizes choice, accessibility, and prescription drug affordability. Our solutions provide the insight and knowledge to help people lead healthier and more productive lives.
